PetMed Express (NASDAQ:PETS), operating as an online pet pharmacy, is the parent company of PetCareRx. The company provides prescription and non-prescription pet medications directly to consumers, competing with others in the digital and physical pet care space. Investors are watching its financial health closely.
As highlighted by GlobeNewswire, PetMed Express is set to release its fourth-quarter financial results on June 2, 2026. For this quarter, Wall Street analysts have an earnings per share (EPS) estimate of -$0.18. The total revenue for the period is projected to be around $52 million.
The expectation of negative earnings aligns with the company's recent performance. PetMed Express has a negative Price-to-Earnings (P/E) ratio of -0.70, which means the company has not been profitable over the last twelve months. This is further shown by its negative earnings yield of -1.42.
From a valuation standpoint, PetMed Express has a Price-to-Sales ratio of 0.25. This ratio compares the company's stock price to its revenues. A ratio this low suggests that the company's market value is a fraction of its annual sales, which can sometimes attract investors looking for potential turnarounds.
The company’s balance sheet shows a current ratio of 0.89. A current ratio below 1.0 indicates that a company's short-term debts are greater than its short-term assets. However, PetMed Express maintains a very low Debt-to-Equity ratio of 0.02, showing it relies very little on debt to finance its operations.
